^
Association details:
| Biomarker: | NCR3LG1 underexpression |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Correlation of low B7-H6 expression with efficacy of immunotherapy inpatients with melanoma.
Published date:
05/25/2023
Excerpt:
...the patients was divided into high group (B7-H6 expression＞3.14) and low group (B7-H6 expression≤3.14). The results showed that low group was significantly associated with longer overall survival (p value = 0.048) in cohort of melanoma patients treated with anti-PD1 ICI, which was consistent with our previous results that low expression of B7-H6 group was correlated with better immune microenvironment.
DOI:
10.1200/JCO.2023.41.16_suppl.e21556